Search results for

Our next Managing IP webinar is taking place on Tuesday June 14 and is titled “PTAB Trials by the Numbers”. Partners from Fitzpatrick Cella Harper & Scinto will provide a statistical analysis of inter partes review and covered business method trials at the Patent Trial and Appeal Board

In a guest post, USPTO Commissioner for Trademarks Mary Boney Denison explains the TM5 ID List Project

South African government endorses the 2014/15 R&D tax incentive scheme and IP Consultative Framework; AdWord keyword bidding is fair game in South Africa; TRIPS Council meetings in June and July; TRIPs Protocol reaches 76 signatories; MPP signs patent licence deal with generic manufacturers; ARIPO’s draft Arusha Protocol Regulations reviewed; INTA comes to Africa in September - Kingsley Egbuonu summarises Africa-related IP news in recent weeks

Nokia and Samsung’s cross licence, a letter from 45 professors calling for venue reform, Adidas suing Skechers, a report criticising Yahoo’s patent portfolio, the Guangzhou IP Court issuing a preliminary injunction and Nintendo’s patent filing were in the intellectual property headlines in the past week

Many of the articles in Managing IP's online archive, which goes back to 1999, are easily accessible via our topic pages. Here's how to find them

A dismissal of a suit against Pfizer indicating consumers cannot be compensated for expenditures on invalidated patents, the NAFTA arbitration hearing of Eli Lilly’s complaint against the government, IP agents getting confidentiality privilege, the Federal Court awarding Janssen nearly C$20 million, and Brexit putting the brakes on CETA were among recent Canadian patent stories

Canada is continuing to amend its intellectual property acts to allow it to join international treaties, plain packaging legislation is being considered, and the Quebec government has proposed legislation to require businesses to use both French and English versions of their outside signage

In a unanimous en banc decision in The Medicines Company v Hospira, the Federal Circuit addressed and clarified the “on sale” bar, a source of much anxiety for pharmaceutical companies

The Federal Circuit has provided some guidance on the issue of 180 days’ notice of launch in a recent biosimilars ruling, in Amgen v Apotex, but practitioners say there will be a lot more litigation before the patent dance is fully clarified

The Government Accountability Office has released two reports: one suggesting the USPTO should define quality, reassess incentives and improve clarity; the other suggesting the USPTO should strengthen search capabilities and better monitor examiners' work